Scholarlink

Background <p>Non-small cell lung cancer (NSCLC) involves mutations in the epidermal growth factor receptor&#xa0;(<i>EGFR</i>) gene, which can be categorized as common and uncommon mutations. Among the uncommon mutations, <i>EGFR</i> exon 20 mutations occur most frequently. Of these, <i>EGFR</i> exon 20 Q787Q is a relatively frequent mutation and is a synonymous polymorphism mutation that does not alter the amino acid sequence of the EGFR protein; however, the effects of this mutation remain unclear. We analyzed the clinicopathological features and prognoses of patients with <i>EGFR</i> exon 20 Q787Q mutation in NSCLC.</p> Methods <p>Patients diagnosed with NSCLC who underwent complete resection at Kitasato University Hospital between 2010 and 2017 were retrospectively reviewed for <i>EGFR</i> mutations. Patients with genetic mutations other than those in <i>EGFR</i> were excluded from the analysis. Patients with <i>EGFR</i> exon 20 Q787Q mutation were compared with those harboring wild-type <i>EGFR</i> using a cohort selected by propensity score matching.</p> Results <p>Among the 693 eligible patients, <i>EGFR</i> mutations were assessed in 349 patients. Of these, 122 (35.0%) displayed common mutations, 72 (20.6%) exhibited uncommon or compound&#xa0;mutations, and 155 (44.4%) showed wild-type <i>EGFR</i>. Within the group exhibiting uncommon or compound&#xa0;mutations, 39 (11.2%) patients presented a single exon 20 Q787Q mutation. When the prognosis and recurrence rates were compared, patients with <i>EGFR</i> exon 20 Q787Q mutation exhibited superior overall survival and lower recurrence rates than those harboring wild-type <i>EGFR</i>.</p> Conclusions <p>Patients with <i>EGFR</i> exon 20 Q787Q mutation, a synonymous polymorphism mutation, exhibited different characteristics compared with those harboring wild-type <i>EGFR</i>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Characteristics of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Q787Q Mutation

  • 期刊论文

  • 发表日期：

    2025年8月24日

查看全文
  • Dai Sonoda,
  • Yasuto Kondo,
  • Raito Maruyama,
  • Shunsuke Mitsuhashi,
  • Satoru Tamagawa,
  • Masahito Naito,
  • Masashi Mikubo,
  • Kazu Shiomi,
  • Yukitoshi Satoh

摘要

Background

Non-small cell lung cancer (NSCLC) involves mutations in the epidermal growth factor receptor (EGFR) gene, which can be categorized as common and uncommon mutations. Among the uncommon mutations, EGFR exon 20 mutations occur most frequently. Of these, EGFR exon 20 Q787Q is a relatively frequent mutation and is a synonymous polymorphism mutation that does not alter the amino acid sequence of the EGFR protein; however, the effects of this mutation remain unclear. We analyzed the clinicopathological features and prognoses of patients with EGFR exon 20 Q787Q mutation in NSCLC.

Methods

Patients diagnosed with NSCLC who underwent complete resection at Kitasato University Hospital between 2010 and 2017 were retrospectively reviewed for EGFR mutations. Patients with genetic mutations other than those in EGFR were excluded from the analysis. Patients with EGFR exon 20 Q787Q mutation were compared with those harboring wild-type EGFR using a cohort selected by propensity score matching.

Results

Among the 693 eligible patients, EGFR mutations were assessed in 349 patients. Of these, 122 (35.0%) displayed common mutations, 72 (20.6%) exhibited uncommon or compound mutations, and 155 (44.4%) showed wild-type EGFR. Within the group exhibiting uncommon or compound mutations, 39 (11.2%) patients presented a single exon 20 Q787Q mutation. When the prognosis and recurrence rates were compared, patients with EGFR exon 20 Q787Q mutation exhibited superior overall survival and lower recurrence rates than those harboring wild-type EGFR.

Conclusions

Patients with EGFR exon 20 Q787Q mutation, a synonymous polymorphism mutation, exhibited different characteristics compared with those harboring wild-type EGFR.